This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Special Investigation in Patients With Rheumatoid Arthritis (Combo Study; Adalimumab With High Dose Methotrexate)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT01736189
First received: November 27, 2012
Last updated: April 20, 2017
Last verified: April 2017
  Purpose
In the usual clinical setting, patients with Rheumatoid Arthritis who receive adalimumab (Humira®) and high-dose Methotrexate (≥12 mg/week) will be investigated prospectively for effectiveness according to Disease Activity Score 28, modified Total Sharp Score, and other measures, as well as safety in terms of the incidence and pattern of occurrence of adverse drug reactions.

Condition
Rheumatoid Arthritis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Special Investigation in Patients With Rheumatoid Arthritis (Combo Study : Adalimumab With High Dose MTX)

Resource links provided by NLM:


Further study details as provided by AbbVie ( AbbVie (prior sponsor, Abbott) ):

Primary Outcome Measures:
  • Disease activity Score 28 [ Time Frame: at week 12 ]
  • Disease activity Score 28 [ Time Frame: at week 24 ]
  • Disease activity Score 28 [ Time Frame: at week 52 ]

Secondary Outcome Measures:
  • Clinical disease activity index [ Time Frame: at week 12 ]
  • Clinical disease activity index [ Time Frame: at week 24 ]
  • Clinical disease activity index [ Time Frame: at week 52 ]
  • Simplified disease activity index [ Time Frame: at week 12 ]
  • Simplified disease activity index [ Time Frame: at week 24 ]
  • Simplified disease activity index [ Time Frame: at week 52 ]
  • X-ray findings for hands and feet [ Time Frame: at week 52 ]
  • Health Assessment Questionnaire [ Time Frame: at week 12 ]
  • Health Assessment Questionnaire [ Time Frame: at week 24 ]
  • Health Assessment Questionnaire [ Time Frame: at week 52 ]
  • Number of patients with adverse events [ Time Frame: at week 52 ]
    Occurrence of adverse event (yes or no), nature of adverse events, date of onset, seriousness,clinical course of adverse events, outcome, measures, causal relationship between the event and Humira


Estimated Enrollment: 350
Study Start Date: September 14, 2012
Estimated Study Completion Date: August 1, 2017
Estimated Primary Completion Date: August 1, 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts
Humira
those with an exposure

  Eligibility

Ages Eligible for Study:   16 Years to 99 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Single-arm, Multi-center, Prospective Cohort
Criteria

Inclusion Criteria:

The subjects of this study are RA patients and to whom adalimumab is administered. They should be satisfying the following conditions:

  • Disease duration of RA ≤2 years
  • MTX administration ≥3 months
  • Dose of MTX ≥12mg/week
  • DAS28-CRP >3.2

Exclusion Criteria:

  • Patients who have been previously treated with biologics (including TNF inhibitors others)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01736189

  Show 144 Study Locations
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Investigators
Study Director: Sarina Kurimoto, MD Abbvie GK
  More Information

Additional Information:
Responsible Party: AbbVie (prior sponsor, Abbott)
ClinicalTrials.gov Identifier: NCT01736189     History of Changes
Other Study ID Numbers: P13-684
Study First Received: November 27, 2012
Last Updated: April 20, 2017

Keywords provided by AbbVie ( AbbVie (prior sponsor, Abbott) ):
Rheumatoid arthritis

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Adalimumab
Anti-Inflammatory Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on June 27, 2017